Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000538257 | SCV000625464 | likely benign | Hereditary nonpolyposis colorectal neoplasms | 2025-01-13 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002420348 | SCV002677034 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-07-17 | criteria provided, single submitter | clinical testing | The c.792+4C>T intronic variant results from a C to T substitution 4 nucleotides after coding exon 4 in the MSH2 gene. This nucleotide position is poorly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will not have any significant effect on splicing; however, direct evidence is insufficient at this time (Ambry internal data). Based on the available evidence, the clinical significance of this variant remains unclear. |
Color Diagnostics, |
RCV002420348 | SCV004356632 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-05-17 | criteria provided, single submitter | clinical testing | This variant causes a C to T nucleotide substitution at the +4 position of intron 4 of the MSH2 gene. To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with MSH2-related disorders in the literature. This variant has been identified in 1/250294 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |